Counterpoint: Prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: The case for prophylaxis

Clinical Infectious Diseases

Volumn 40, Issue 5, 2005, Pages 709-712

  Snydman, David R ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COTRIMOXAZOLE; GANCICLOVIR; VALGANCICLOVIR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG COST; HIGH RISK PATIENT; HUMAN; INFECTION RISK; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PNEUMOCYSTIS JIROVECI; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; HUMANS; ORGAN TRANSPLANTATION;

EID: 15044358787     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427509     Document Type: Review

References (44)

1. Snydman DR. Infection in solid organ transplantation. Transpl Infect Dis 1999; 1:21-8.
2. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261:3607-9.
3. Munoz-Price LS, Slifkin M, Ruthazer R, et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004; 39:1293-9.
4. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997; 350:1729-33.
5. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100:61-6.
6. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340:1462-70.
7. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4:928-36.
8. Falagas ME, Paya C, Ruthazer R, et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation. Transplantation 1998; 66:1020-8.
9. Paya CV. Economic impact of cytomegalovirus in solid organ transplantation. Transpl Infect Dis 2001; 3(Suppl 2):14-9.
10. Singh N. Late-onset cytomegalovirus disease as a significant complication in organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005; 40:704-8 (in this issue).
11. Koetz AC, Delbruck R, Furtwangler A, et al. Cytomegalovirus PP65 antigen-guided pre-emptive therapy with ganciclovir in solid organ transplant recipients: a prospective, doubleblind, placebo-controlled study. Transplantation 2001; 72:1325-7.
12. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IG. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 2000; 70:717-22.
13. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185:854-60.
14. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med 1995; 123:18-26.
15. Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991; 324: 1057-9.
16. Brennan DC, Storch GA, Lippman BJ. Preemptive ganciclovir therapy in renal transplantation. Ann Intern Med 1996; 124:693.
17. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83-6.
18. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001; 33:1397-405.
19. Bienvenu B, Thervet E, Bedrossian J, et al. Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient. Transplantation 2000; 69:182-4.
20. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of gancidovir-resistant cytomegalovirus disease among solid organ transplant recipients. Lancet 2000; 356:645-9.
21. Isada CM, Yen-Lieberman B, Lurain NS, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis 2002; 4:189-94.
22. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44:2811-5.
23. Hummel M, Abecassis MM. A model for reactivation of CMV from latency. J Clin Virol 2002; 25(Suppl 2):S123-36.
24. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185: 20-7.
25. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189:1615-8.
26. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Valganciclovir Solid Organ Transplant Study Group. Am J Transplant 2004; 4:611-20.
27. Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001; 33:e62-8.
28. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3:731-5.
29. Shibolet O, Ilan Y, Kalish Y, et al. Late cytomegalovirus disease following liver transplantation. Transpl Int 2003; 16:861-5.
30. Grob JP, Grundy JE, Prentice HG, et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet 1987; 1(8536):774-6.
31. Roy DM, Brenner MK, Cook D, Duncan RI, Griffiths PD, Grundy JE. Transfer of humoral immunity against cytomegalovirus proteins following transplantation of T-cell-depleted allogeneic bone marrow from seropositive donors. J Med Virol 1993; 41:150-8.
32. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184:1461-4.
33. Corales R, Chua J, Mawhorter S, et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? Transpl Infect Dis 2000; 2:133-9.
34. Blanche G, Josien R, Douillard D, Bignon JD, Cesbron A, Soulillou JP. The influence of HLA A-B-DR matching on cytomegalovirus disease after renal transplantation. Transplantation 1992; 54:871-4.
35. Schnitzler MA, Lowell JA, Hmiel SR et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching. J Am Soc Nephrol 2003; 14:780-5.
36. Sagedal S, Nordal KP, Hartmann A, et al. Preemptive therapy of CMV pp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant 2003; 18:1899-908.
37. Benz C, Holz G, Michel D, et al. Viral escape and T-cell immunity during ganciclovir treatment of cytomegalovirus infection: case report of a pancreatico-renal transplant recipient. Transplantation 2003; 75:724-7.
38. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High dose aciclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: a randomized trial. Ann Intern Med 1994; 120: 375-81.
39. Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64:1843-6.
40. Hart GD, Paya CV. Prophylaxis for CMV should now replace preemptive therapy in solid organ transplantation. Rev Med Virol 2001; 11:73-81.
41. Kalil AC, Levitsky J, Lyden E, et al. Preemptive therapy (PRE) and universal prophylaxis (PRO) for cytomegalovirus (CMV) in solid organ transplant recipients (SOT): a meta-analyses [abstract L39]. In: Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston). Alexandria, VA: Infectious Diseases Society of America, 2004:167.
42. Slifkin M, Ruthazer R, Warshaw A, et al. Improved cytomegalovirus (CMV) prevention is associated with increased survival in orthotopic liver transplantation (OLT) [H-1119]. In: Program and abstracts of the 41st International Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). 2001:297.
43. Freeman R, Slifkin M, Ruthazer R, et al. Intense CMV prophylaxis reduces rejection in orthotopic liver transplantation (OLT). In: Program and abstracts of the 2000 American Transplant Congress Meeting (Washington, DC). 2002.
44. Das A. Cytomegalovirus infection in solid organ transplantation: economic implications. Pharmacoeconomics 2003; 21:467-75.